Table 1.
Clinical features of Testicular Germ-Cell Tumors.
| Response to CT, (n, %) | NS-TGCT Cohort (n = 32) | ||
| Resistant (n = 14) | Sensitive (n = 18) | All samples (n = 32) | |
| 14 (43.75) | 18 (56.25) | ||
| Age at diagnosis, years: median, (IQR) | 25 (21–31) | 22 (19–24) | 24 (21–31) |
| p = 0.13 | |||
| Stage according to TNM from AJCC 8th Edition (n, %) | |||
| IS | 0 | 1 (5.56) | 1 (3.13) |
| II | 1 (7.14) | 9 (50) | 10 (31.25) |
| III | 13 (92.86) | 8 (44.44) | 21 (65.63) |
| p″ = 0.008 * | |||
| Histologic Subgroup (n, %) | |||
| Embryonal carcinoma (EC) | 10 (71.43) | 14 (77.78) | 24 (75) |
| Teratoma (TE) | 9 (64.29) | 13 (72.22) | 22 (68.75) |
| Yolk Sac Tumors (YST) | 10 (71.43) | 13 (72.22) | 23 (71.88) |
| Choriocarcinoma (CH) | 2 (14.29) | 2 (11.11) | 4 (12.5) |
| Seminoma cells (SE) | 6 (42.86) | 2 (11.11) | 8 (25) |
| Malignant transformation (MT) | 2 (14.29) | 0 | 2 (6.25) |
| Mixed histology ** | 13 (92.86) | 17 (94.44) | 30 (93.75) |
| Metastases (n, %) * | |||
| Lung | 11 (78.57) | 6 (33.33) | 15 (46.88) |
| Lymph Node | |||
| Mediastinum (MLN) | 4 (28.57) | 2 (11.11) | 6 (18.75) |
| Retroperitoneum (RPLN) | 14 (100) | 14 (77.78) | 26 (87.5) |
| Inguinal (ILN) | 2 (14.29) | 3 (16.67) | 5 (15.63) |
| Non pulmonary visceral metastases | |||
| Liver | 4 (28.57) | 1 (5.56) | 4 (12.5) |
| Bone | 1 (7.14) | 0 | 1 (3.13) |
| Brain (CNS) | 2 (14.29) | 0 | 2 (6.25) |
| No metastatic site | 0 | 2 (14.29) | 2 (6.25) |
| p = <0.001 * | 30/32 (93.75%) | ||
| Prognostic group according to IGCCCG (n, %) | |||
| Good | 1 (7.14) | 11 (61.11) | 12 (37.5) |
| Intermediate | 5 (35.71) | 3 (16.67) | 8 (25) |
| Poor | 8 (57.14) | 4 (22.22) | 12 (37.5) |
| p′ = 0.01 * | |||
| CT Regimen *** (n, %) | |||
| BEP | 1/14 (7.14) | 18/18 (100) | 19/32 (59.38) |
| BEP-RT | 1/14 (7.14) | 0/18 | 1/32 (3.13) |
| BEP-TIP | 4/14 (28.57) | 0/18 | 4/32 (12.5) |
| BEP-TIP + CISCA | 5/14 (35.71) | 0/18 | 5/32 (15.63) |
| BEP-CISCA | 1/14 (7.14) | 0/18 | 1/32 (3.13) |
| BEP-Doxorubicin | 1/14 (7.14) | 0/18 | 1/32 (3.13) |
| EP-VeIP-CISCA | 1/14 (7.14) | 0/18 | 1/32 (3.13) |
| Response to platinum-based chemotherapy according to the RECIST version 1.1 (n, %) | |||
| Complete Response (CR) | 0 | 8 (44.44) | 8 (25) |
| Partial Response (PR) | 7 (50) | 9 (50) | 16 (50) |
| Overall Response Rate (ORR) | 7 (50) | 18 (100) | 25 (78.13) |
| Stable Disease (SD) | 0 | 1 (5.56) | 1 (3.13) |
| Progressive Disease (PD) | 6 (42.86) | 0 | 6 (18.75) |
| Not Evaluable (NE) | 1 (7.14) | 0 | 1 (3.13) |
| p″ = 0.01 * | |||
| Outcome (n, %) | |||
| Alive | 2 (14.29) | 16 (88.89) | 18 (56.25) |
| Death | 8 (57.14) | 1 (5.56) | 9 (28.13) |
| Unknown | 4 (28.57) | 1 (5.56) | 5 (15.63) |
| p″ = 0.002 * | |||
Abbreviations: CT, chemotherapy; BEP, Bleomycin/Etoposide/Cisplatin; IQR, Interquartile Range; TNM, Tumor/Node/Metastasis; MLN, Mediastinum lymph Nodes; RPLN, Retroperitoneum Lymph Nodes; ILN, Lymph Nodes; AJCC, American Joint Committee on Cancer; RT, Radiotherapy; TIP, Paclitaxel/Ifosfamide/Cisplatin; CISCA, Cisplatin/Cyclophosphamide/Adriamycin; VeIP, Vinblastine/Ifosfamide/Cisplatin; EP, Etoposide/Cisplatin; IGCCCG, International Germ-Cell Cancer Collaborative Group; RECIST, Response Evaluation Criteria In Solid Tumors v1.1. p: Student’s t-test Sensitive versus Resistant. p′: Mann–Whitney´s U-test frequency of metastatic site per patient, Sensitive versus Resistant. p″: Fisher’s exact/Chi-squared test Sensitive versus Resistant. * Patients that presented metastases in that site at time of diagnosis. ** Mixed histology when 2 or more histological subtypes were identified according to the 2016 WHO Classification of Tumors of the Urinary System and Male Genital Organs. *** 2 to 4 platinum-based chemotherapy.